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Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterised by 
central obesity and insulin resistance and comprises a spectrum of 
disease severity from steatosis, to hepatic necro-inflammation and 
fibrosis termed non-alcoholic steatohepatitis (NASH). NASH is the 
third most common indication for liver transplantation in the United 
States and is predicted to overtake hepatitis C as the most common 
indication for liver transplantation by 2025 [1]. Patients with NASH 
are also at high risk for cardiometabolic complications such as type 2 
diabetes and cardiovascular disease [2].
Attempts at pharmacotherapy have been disappointing [3] and 
there is general consensus that lifestyle intervention remains the 
principal approach to treatment [4,5], but our understanding of the 
distinct role of exercise on liver injury remains unclear. A recent meta-
analysis of exercise protocols in patients with established NAFLD, 
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Abstract
Aims: Type 2 diabetes is a risk factor for the development and progression of non-alcoholic fatty liver disease 
(NAFLD). Lifestyle intervention is the principal treatment for NAFLD however the effects of exercise alone on the 
histological and metabolic severity of NAFLD are unclear. This study assessed the effects of 6 months exercise 
training and diet-induced weight loss on insulin resistance and liver histologyin overweight patients with NAFLD.
Methods: 21 patients were randomised to circuit exercise (EX) training (60 min×3/week) or dietary induced 
weight loss (DIWL) (-500 kcal/d). Insulin sensitivity (euglycaemic-hyperinsulinemic clamp with tracer), adiposity (CT 
scan) and histology (liver biopsy) were assessed at 0 and 6 months. 
Results: Weight decreased by 9.7 ± 4.6% (-6.7 ± 6.3 kg p=0.02) with DIWL but was unchanged after EX. Both 
groups equivalently reduced visceral fat (DIWL -22 ± 24% p=0.06 and EX -18 ± 18% p<0.05) while only EX increased 
lean mass (+3% p<0.01). DIWL markedly reduced steatosis (73 ± 36% to 23 ± 32%, p<0.05) and NAFLD activity 
score NAS (median (range) 5 (1-7) to 1 (0-5), p<0.05). After EX, there was no change in steatosis or NAS. A decrease 
in steatosis was associated with weight loss (rs=0.82, p<0.0001). An improvement in fibrosis was associated with a 
decrease in steatosis (rs=0.64, p=0.02). Small improvements in fasting hepatic insulin resistance were similar in both 
groups while changes in muscle insulin resistance were not significant.
Conclusions: Circuit exercise is safe and efficacious for improving cardiometabolic risk factors in patients 
with NAFLD, however this dose of circuit training, without concomitant weight loss, was insufficient for histological 
improvements in NAFLD. The pilot study outcomes should stimulate further development of different exercise 
protocols (type, frequency and intensity) to address disease-specific conditions in those with severe insulin resistance.
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Patients and Methods
Ethics statement
The study was approved by the Human Research Ethics Committees 
of the Princess Alexandra Hospital and the University of Queensland 
and registered through the Australian and New Zealand Clinical Trials 
Registry, ACTRN12612001087842. Written informed consent was 
obtained from all participantsand the study protocol conforms to the 
ethical guidelines of the 1975 Declaration of Helsinki. Recruitment and 
follow up occurred between 2009 and 2010. The CONSORT diagram is 
presented as Figure 1.
Participants
Twenty-one patients with NAFLD participated in the study, while 
16 healthy control subjects acted as a comparator group at baseline 
only. Patients were recruited from outpatient clinics. Exclusion criteria 
included the presence of other liver diseases or evidence of cirrhosis, 
alcohol consumption >40 g/day (males) or >20 g/day (females), and 
diabetes. Controls were non-smoking, non-obese adults with minimal 
alcohol intake, normal liver enzymes, no evidence of liver disease and 
no features of the metabolic syndrome [12]. In individuals meeting 
these same criteria, the prevalence of steatosis has been shown to be 
demonstrated that even low-intensity exercise may reduce hepatic 
steatosis [6]. However, all exercise interventions to date have been short 
duration (≤4 months) and rely on magnetic resonance spectroscopy 
(MRS) assessment of total hepatic triglyceride content, so effects on 
disease severity remain unknown [7].
Visceral fat and altered adipokines may contribute to insulin 
resistance and steatosis [8,9]. Exercise that includes both resistance 
and aerobic components, such as circuit training, reduce visceral fat 
while maintaining muscle mass [10]. However, the effect of circuit 
training on sites of insulin resistance and lipid metabolism is not clear. 
In addition, if physical activity is shown to benefit NASH, its uptake 
in this population will depend on acceptance of the type of exercise 
prescription. Low- to moderate-intensity circuit training may be more 
appealing to obese patients with limited physical functioning [11].
We hypothesize that circuit exercise training without weight loss 
will have beneficial effects on liver histology, insulin resistance and 
body composition. The primary outcome measure is steatosis assessed 
by histology and the secondary outcome measures include peripheral 
and hepatic insulin resistance, visceral adiposity and adipokines. This 
study assessed the histological and metabolic effects of 6 months circuit 
exercise training (EX) compared with diet-induced weight loss (DIWL) 
in overweight patients with biopsy-proven NAFLD.
Figure 1: Consort diagram showing patient recruitment and follow up during the study.
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<5% [13]. Control subjects did not undergo liver biopsy as this was 
deemed unethical.
General design
At baseline 21 patients with NAFLD were randomised by the study 
co-ordinator, using random number generator, into one of two groups; 
dietary induced weight loss (DIWL) (without changes to physical 
activity) or a circuit exercise training program (EX) without changes 
to dietary intake. The exercise program involved 3 sessions per week 
of circuit exercise training for 6 months, without dietary changes, 
with the aim to improve physical fitness and muscle strength without 
significant body weight loss. Exercise was conducted using pneumatic 
resistance training equipment (AbHurOy, Kokkola, Finalnd). Each 
circuit consisted of 15 moderate-intensity resistance exercises covering 
the main muscular groups. Some machines were bi-functional, 
allowing participants to exercise two different muscular groups, usually 
antagonistic. On the bi-functional machines, participants exercised 
alternatively the agonist or the antagonist muscle. The training program 
consisted of 30 seconds exercise intervals and 30 seconds rest periods, 
during which participants moved to the next station and prepared 
themselves for the following exercise period. A digital timed audio 
signal was used to indicate the start and the end of the 30 seconds 
exercise or rest period. Training intensity over the whole duration of 
the training program was fixed at 50% of 1 repetition maximum (1-
RM). Number of circuits, and consequently session duration, was 
progressively increased from one circuit (12 min) in week one to 5 
circuits in week 12 (60 minutes) and was kept constant from week 16 to 
the end of the training program (week 24). A 1-RM was completed on 
each of the 15 exercises the week prior to the beginning of the program, 
and was then reassessed every four weeks to account for any strength 
adaptations over the course of the training period.
The 6 month dietary-induced weight loss intervention was 
individually tailored to induce an energy restriction calculated (based 
on Harris-Benedict predicted energy requirements and sedentary 
activity factors) for 5 to 10% body weight loss over a 16-week intensive 
phase whereby patients were reviewed weekly by a Dietician. This was 
followed by an 8-week weight maintenance phase involving dietetic 
review every two weeks. Participants were instructed not to change 
their usual physical activity habits. The intervention was supported 
by an educational manual, which included information about energy 
content of food portions, macro- and micronutrient content of 
individual foods and combination dishes, food label reading, shopping, 
cooking and eating-out guidelines, motivational tools and goal setting 
skills and activities. A dietary composition of 40% carbohydrate, 40% 
fat and 20% protein sources of energy was encouraged, with specific 
advice on reduced saturated fat, lowering sugar (including reduced 
sugary drinks), avoiding micronutrient poor/energy dense food 
options and aiming for regular meal patterns. Weekly weight and waist 
measures and 24-hour diet recall interviewing assisted compliance 
and encouraged ongoing self-monitoring. Motivational interviewing 
and behavioural management techniques were used throughout the 
program.
Physical activity and fitness
Physical activity was measured using RT3 accelerometers 
(StayHealthy Inc., Monrovia, CA) worn for 7 days at months 0, 3 and 
6. Activity was categorised according to a vector magnitude of ≤1000 
counts/min (sedentary); 1001-2000 counts/min (moderate) or >2000 
counts/min (vigorous). Peak oxygen consumption (VO2peak) was 
determined with a graded exercise test on cycle ergometer (Excalibur 
Sport, Lode, Groningen, Netherlands).
Histological analysis of liver biopsy
Liver biopsy specimens were fixed in 10% neutral buffered formalin, 
embedded in paraffin, and reviewed and scored in a blinded fashion 
by an expert hepatopathologist (AC). The proportion of hepatocytes 
affected by steatosis was estimated as a percentage. The severity of 
liver injury was assessed using the Clinical Research Network NAFLD 
activity score (NAS) and fibrosis stage [14]. A diagnosis of steatosis 
alone or NASH was made using conventional histologic criteria, 
independent of NAS [15].
Body composition
Fat mass and fat-free mass (FFM) were measured by dual-energy 
X-ray absorptiometry (GE Lunar Prodigy enCore 2005, General 
Electric, Madison, WI). Distribution of abdominal fat (visceral adipose 
tissue, VAT and subcutaneous adipose tissue, SAT) was determined by 
computed tomography scan (Philips Brilliance 16, Cleveland, OH) as 
previously described [16].
Hyperinsulinemic-euglycemic clamp
Insulin sensitivity was evaluated by a 2-hour hyperinsulinemic-
euglycemic clamp [17], with a protocol mirroring that of Bugianesi 
et al. [18] (detailed in supporting material). All experiments were 
performed after an overnight fast (8-10 hours) with a minimum of 72 
hours since any exercise training and weight stable for minimum of 
2 weeks. Basal endogenous glucose production (EGP) was calculated 
as the glucose rate of appearance (Ra) with a steady-state equation for 
stable isotope tracers. During the clamp, total glucose Ra was calculated 
using non steady-state Steele’s equation [19]. EGP during the clamp was 
estimated as the difference between total Ra and the exogenous glucose 
infusion rate, and percent suppression from basal calculated. Fasting 
hepatic insulin resistance index (Hepatic-IR) was calculated [20]. Total 
glucose disposal (TGD), was calculated by adding the mean rate of EGP 
during hyperinsulinemia to the steady state glucose infusion rate. The 
peripheral insulin sensitivity index (TGD/I), was calculated by dividing 
TGD by steady state 2 hr insulin concentrations, multiplied by 100 [17].
Biochemical analysis
Insulin was assayed using an immunoenzymatic assay with 
chemiluminescence detection (Beckman Coulter, Brea, CA). 
Cholesterols and triglycerides were assayed by an enzymatic colorimetric 
assay (Roche, SanFranciso CA). Plasma non-esterified fatty acids 
(NEFA) were measured with an in vitro enzymatic colorimetric method 
(Wako chemicals, Richmond, VA). An index of adipocyte insulin 
resistance (Adipo-IR) was calculated [21]. Plasma β-hydroxybutyrate, 
an index of hepatic lipid oxidation [22], was measured enzymatically 
(Stanbio, Boerne, TX). TNF-alpha was measured by high sensitivity 
milliplex kit (Millipore, Billerica, MA, USA). HsCRP was measured 
using an immunoturbiometric method (Kamiya, Seattle, WA, USA). 
Total and high molecular weight (HMW) adiponectin was assessed by 
ELISA (ALPCO (multimeric) kit, ALPCO, Salem, NH, USA). 
Indirect calorimetry
Indirect calorimetry (TrueOne 2400 Metabolic Measurement 
System, Parvo Medics, UT) was performed under fasted and insulin-
stimulated conditions. Substrate oxidation rates were calculated using 
stoichiometric equations [23].
Statistical analysis
Sample size calculationbased on our previous study of weight loss 
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(paired biopsies from 10 patients after diet and exercise combined) in 
patients with chronic liver disease [24], a sample size of 8 subjects will 
have 80% power to detect a difference in mean steatosis of 1 point with 
a standard deviation of 0.91, at p<0.05. A 25% difference in glucose 
disposal rate requires 5-8 subjects for within group analysis [25]. All 
data were expressed as means ± standard deviation, or median (range) 
if not normally distributed. Data were analyzed as intention to treat for 
all variables except histology, whereby only those undergoing a second 
biopsy were included in paired analysis. Unpaired t-test or Mann-
Whitney U test was used to compare groups at baseline; proportions 
were compared by the Fischer’s exact test. Within group difference 
after intervention was assessed using a paired t-test or a Wilcoxon 
matched-pair signed rank test (2 samples) if not normally distributed. 
Pearson’s correlation was used to test for associations between normally 
distributed variables, while Spearman’s rank test was used for variables 
not normally distributed. A treatment effect was assessed by 2 (group) 
× 2 (time) RMANOVA and/or independent t-test of each within 
group variable change. Multiple linear regressions were used to adjust 
for confounding variables. P values less than 0.05 were considered 
statistically significant. All analyses performed using IBM SPSS for 
Macintosh, version 20.
Results
Subject compliance and adverse events
Four patients did not complete the study: two each from DIWL 
and EX arms due to work, study commitments and unexpected care 
responsibilities. Attendance to EX was >90% with no adverse events. 
Participants undertook little physical activity at baseline with 98 ± 2% 
of the day spent in sedentary or no activity. The proportion of the day 
(excluding exercise training) spent in sedentary, moderate or vigorous 
activity did not change during the study. 
Baseline characteristics 
Baseline characteristics (Table 1) of DIWL and EX groups were 
similar, with marked central obesity and cardiovascular risk factors. 
Patients demonstrated severe insulin resistance with fasting insulin 
levels seven times higher, hepatic-IR five times higher and peripheral 
glucose disposal less than half that of the lean control group. More than 
85% of patients met diagnostic criteria for NASH.
Metabolic response
Aerobic fitness (VO2peak) improved by 17% with EX (p<0.0001) but 
Healthy control
(n=16)‡
NAFLD diet (n=8) NAFLD exercise (n=13)
Pre Post Pre Post
Age (years) 40 ± 12 45 ±14 - 50 ± 9 -
Gender (M/F) 11/5 4/4 - 9/4 -
BMI (kg/m2) 23 ± 3‡ 35 ± 8 32 ± 7 * 33 ± 6 33 ± 5
Waist (cm)
Body fat (%)
82 ± 8‡
23± 6
111 ± 17
38 ± 8
104 ± 20 *
35  ± 11
114 ± 18
39 ±8
109 ± 16**
34 ± 7**
Diastolic BP (mmHg) 72 ± 7‡ 80 ± 9 75 ±12 88 ± 9 84±10
Systolic BP (mmHg) 115 ± 8‡ 126 ± 13 117 ± 13 * 140 ± 19 138 ± 18
Fasting glucose (mg/dl) 90 ± 7‡ 95 ± 7 94 ± 13 99 ± 9 95 ± 7
Fasting insulin (µU/ml) 3 ± 2‡ 19 ± 15 13 ± 7 24 ± 22 15 ± 10
Fasting triglycerides (mg/dl) 44 ± 18‡ 142 ± 71 124 ± 78 177 ± 97 177 ± 115
Fasting HDL cholesterol (mg/dl) 53 ± 12‡ 37 ± 12 40 ± 11 35 ± 10 40 ± 10 **
ALT (U/L) 23 ± 12‡ 70 ± 58 51 ± 47 61 ± 30 53 ± 34
Patients with the metabolic syndrome n (%) 0 (0) 5 (63) 5 (63) 8 (62) 8 (62)
TNFα (pg/ml)
hsCRP (mg/L)
Total adiponectin (µg/ml)
HMW adiponectin (µg/ml)
4.1(1.6-18.3)
0.6(0.1-3.7)‡
5.6 ± 3.1‡
2.7 ± 1.8‡
5.0(2.1-12.0)
2.7(0.5-9.7)
3.1 ± 1.3
1.1 ± 0.8
4.5(2.1-6.5)
1.7(0.5-9.0)
3.8 ±1.4*
1.7 ± 1.1*
5.1(3.8-17.3)
1.5(0.7-4.8)
3.6 ± 1.6
1.5 ± 1.0
5.7(3.5-17.3)
1.0(0.2-4.8)
3.4 ± 1.8
1.2 ±1.0
Glucose metabolism
Clamp plasma insulin (µU/ml)
Clamp plasma glucose (mg/dl)
Muscle
TGD (mg/kgFFM/min)
TGD/I (mg/kgFFM/min)/(mU/L)  
Oxidative GDR (mg/kgFFM/min)
Non-oxidative GDR (mg/kgFFM/min)
Liver
Fasting EGP (µmol/kg/min)
Hepatic-IR (μmol/kgFFM/min/pmol/L)
Suppression EGP (%)
Lipid metabolism
Fasting NEFA (mmol/L)
Adipose tissue-IR (mmol/pmol/L)
β-Hydroxybutyrate (mmol/L)
Fasting whole body fat oxidation (mg/kg/min)
49 ± 10‡
79.2 ± 7.2
9.1 ± 2.3‡
19.8 ± 7.8‡
3.7 ± 0.7
5.3 ± 2.7‡
12.2 ± 2.7
5.4 ± 3.4‡
94 ± 11
0.61 ± 0.19
15.2 ± 8.3‡
0.14 ± 0.07‡
1.01 ± 0.34‡
76 ± 28
79.2 ± 7.2
4.3 ± 1.4
6.2 ± 2.7
3.2 ± 0.9
1.0 ± 1.0
10.1 ± 1.0
21.1 ± 16.1
91 ± 11
0.62 ± 0.16
84.3 ± 69.4
0.08 ± 0.02
0.73 ± 0.24
70 ± 22
84.6 ± 7.2
5.2±1.6
7.8 ± 2.6
3.3 ± 0.8
1.9 ± 1.4
10.9 ± 2.0
15.6 ± 8.2
95 ± 6
0.64 ± 0.21
47.4 ± 24.1
0.10 ± 0.04*
0.85 ± 0.32
81 ± 26
84.6 ± 7.2
4.5±1.7
6.5 ± 4.3
3.6 ± 1.7
0.9 ± 2.3
10.9 ± 1.7
26.2 ± 21.5
86 ± 12
0.56 ± 0.18
94.3 ± 90.4
0.10 ± 0.03
0.77 ± 0.15
79 ± 18
81.9 ± 7.2
5.3 ± 1.6*
7.3 ± 4.0
2.9 ± 1.1
2.4 ± 1.3 *
10.9 ± 2.3
16.4 ± 11.8
98 ± 4*
0.60 ± 0.23
60.3 ± 42.9
0.11 ± 0.06
0.88 ± 0.26
Values are mean ± SD or median (range) for non-parametric variables. There was no difference between NAFLD groups in any variable at baseline. Intention-to-treat 
analysis performed for pre- and post-analysis.
‡P<0.01 for independent t-test (or Wilcoxon matched pairs test) comparisons with total NAFLD group at baseline
*p<0.05, **p<0.01 paired t-test for change within group
p<0.05 for treatment effect between diet and exercise groups assessed by RMANOVA (time × group) or independent t-test of delta at 6 months
Table 1: Characteristics of subjects at baseline (Pre) and after 6 months intervention (Post).
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did not change with DIWL (p=0.52, Figure 2A). DIWL led to weight 
loss of 9.7 ± 4.6% (Figure 2B), with clinically significant decreases in 
SAT (-15 ± 15%, p=0.06) and VAT (-22 ± 24%, p=0.06) and a minor 
decrease in lean body mass (-2 ± 0.4%, p=0.06, Figure 2C and D). 
Weight did not change after EX (Figure 2B), however both SAT (-7 ± 
8%, p<0.05) and VAT (-18 ± 18%, p=0.04) decreased while lean mass 
increased (+3 ± 2%, p<0.01 Figure 2C and D). The two interventions 
had differential effects on features of the metabolic syndrome (Table 
1): DIWL lowered systolic blood pressure, while EX increased HDL 
cholesterol. Fasting triglycerides and ALT remained unchanged with 
both interventions (Table 1). 
Liver histology
At baseline, 18 of the 21 patients had a diagnosis of NASH (median 
NAS=5, range 1-8). Repeat liver biopsy was performed after DIWL 
(n=5) and EX (n=9) (All raw data in Table 2). At baseline, fibrosis 
correlated with severity of insulin resistance in adipose tissue (r=0.59, 
p=0.006) and muscle (TGD r=-0.71, p=0.001), but not in liver (p=0.41).
There was no baseline difference in any clinical variable between 
those who did and did not have a repeat biopsy. In the subset of patients 
with repeat biopsy, within group changes in clinical variables pre and 
post intervention were no different to the full cohort reported except 
that the reduction in VAT after DIWL became statistically significant 
(-36 ± 18%, p<0.05) but was not significantly greater than decrease 
in VAT in patients with a repeat biopsy after EX (p=0.23). DIWL was 
associated with a remarkable improvement in steatosis (73 ± 36% to 23 
± 32% p<0.05 Figure 3A) with 4 out of 5 (80%) decreasing steatosis by 
≥2 scores. All five (100%) patients with re-biopsy showed improvements 
in lobular inflammation, while four (80%) showed reduced hepatocyte 
ballooning (Table 2). The net effect of these changes was a significant 
reduction in NAS (median (range) 5 (1-7) to 1 (0-5), p=0.05, Figure 
3B). In contrast, the histological response to EX was variable with only 
small or no improvements in steatosis (71 ± 32% to 54 ± 36%, p=0.12, 
Figure 3A), only one out of nine (11%) patients improving steatosis by 
≥2 scores, only two of the nine patients improving lobular inflammation 
and therefore no net improvement in the NAS (Figure 3B). The greater 
proportion of patients improving lobular inflammation after DIWL 
compared to EX was statistically significant (Figure 3C and Table 2). 
There were subtle improvements in Brunt fibrosis staging in 60-70% 
of patients that did not reach statistical significance in either group 
(Figure 3D). Overall, an improvement in steatosis correlated with 
degree of weight loss (rs=0.82, p<0.0001; Figure 4A). Improvements 
in fibrosis were associated with the reduction in steatosis (rs=0.64, 
p=0.02; Figure 4B). This persisted after correcting for weight and body 
fat loss (standardized β=0.88, p=0.04). An improvement (decrease) in 
hepatic lobular inflammation was correlated with an increase in HMW 
adiponectin (rs=-0.66, p=0.01) and an improvement (decrease) in 
hepatic-IR (rs=0.56, p=0.04).
Glucose metabolism: Muscle
Total glucose disposal (TGD) was severely impaired in participants 
with NAFLD, but there was considerable variability, ranging from 
the lower end of normal through to profoundly impaired (range 
2.63 to 8.53 mg/kgFFM/min). When corrected for circulating plasma 
insulin levels achieved during the clamp (TGD/I), a variable, non-
significant peripheral response to intervention was observed with an 
improvement in some patients with severe baseline insulin resistance, 
but a paradoxical worsening of insulin resistance in others (Figure 5). 
Muscle insulin sensitivity in NAFLD remained almost one third that of 
lean controls after intervention. Any modest improvement in TGD/I 
gained after intervention was due to an increase in non-oxidative 
glucose disposal (glycogen storage), as oxidative glucose disposal was 
unchanged (Table 1).
Glucose metabolism: Liver
Fasting EGP were within normal ranges in this non-diabetic NAFLD 
group, as was the ability to suppress hepatic glucose under insulin-
stimulation, although these processes occurred with considerably 
Figure 2: Changes in fitness, weight and body composition after the diet and exercise interventions.
Fitness assessed by VO2peak (Panel A), total body weight (Panel B), subcutaneous (SAT) and visceral (VAT) adipose tissue assessed by CT scan (Panel C) and fat free 
mass assessed by DEXA (Panel D), pre and post 6-month DIWL or EX. Bars represent mean ± standard error of the mean. *p<0.05; ***p<0.001.
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higher serum insulin concentrations. The fasting hepatic-IR index 
was thus significantly higher in NAFLD at baseline compared to lean 
controls (Table 1). Improvement in fasting hepatic-IR was similar in 
both groups (Table 1: DIWL 26% decrease, p=0.08; EX 37% decrease, 
p=0.06). 
Lipid metabolism 
Adipose tissue IR index (Adipo-IR) was significantly worse, six 
times higher, in patients with NAFLD compared to lean controls (Table 
1) and was associated with both lower muscle insulin sensitivity (r=-0.6, 
p<0.001) and higher hepatic-IR (r=0.9, p<0.001). In the whole patient 
group, an improvement in Adipo-IR correlated with improvements 
in hepatic-IR (rs=0.67, p=0.004) but not changes in VAT (p=0.12) or 
weight loss (p=0.28). β-hydroxybutyrate was significantly lower in 
patients with NAFLD compared with lean controls (0.09 ± 0.03 vs. 0.14 
± 0.07, p=0.018), indicating there was reduced hepatic fat oxidation. 
Only DIWL resulted in an increase inβ-hydroxybutyrate (increase 
by 25%). In contrast, whole body fasting lipid oxidation increased 
irrespective of intervention type (0.75 ± 0.19 to 0.87 ± 0.28 mg/kg/min, 
p=0.02) and correlated with improved hepatic-IR (rs=-0.55, p=0.03).
Adipokine response
Total serum adiponectin was 40% lower in patients compared to 
lean controls (p=0.008) mainly due to reduced HMW fraction (Table 1). 
Changes in total adiponectin levels were not detected after EX, although 
there was a trend for a selective decrease in the HMW fraction that 
resulted in a significant decrease in the ratio of HMW to total adiponectin 
(SA; 0.37 ± 0.13 to 0.29 ± 0.11, p=0.004). DIWL was associated with a 
significant increase in total adiponectin and increase in the ratio of 
HMW to total adiponectin (SA; 0.34 ± 0.11 to 0.42 ± 15, p<0.05).
Discussion
Therapies that target both liver disease and cardiometabolic risk 
factors are important for NASH. Patients who undertook circuit 
* Reduction in score of  ≥ 2 or ≥ 2 but normalised tissue or was normal at baseline and remained normal
p<0.05 RMANOVA for time x treatment difference between groups at 6 months
DIWL: Diet-induced Weight Loss Intervention; EX: Exercise Intervention; NAS: NAFLD Activity Score; Pts: Patients; NASH: Nonalcoholic Steatohepatitis
§Number of patients with diagnosed NASH at baseline: n=3 in diet group and n=8 in exercise group
Table 2: Raw data of hepatic histologic scores pre and 6 months post-diet and exercise intervention in those patients with a repeat liver biopsy.
Histological Feature
Diet (n=5) Exercise (n=9) P Value DIWL 
vs EXPre Post P Value Pre Post P Value
Steatosis
% hepatocytes affected 73 ± 36 23 ± 32 0.04 71 ± 32 54 ± 36 0.12 0.05
Score – no. of subjects
   0 (<5%) 0 1 0 0
   1 (5-33%) 1 3 2 3
   2 (>33% - 66%) 0 0 0.08 1 1 0.59
   3 (>66%) 4 1 6 5
No. pts with improvement - % 80% 22%
Pts with a reduction in score of ≥2* – no./total no. (%) 4/5(80) 1/9(11) 0.02
Hepatocyte Ballooning 
Score – no. of subjects
   0 (None) 2 4 1 3
   1 (Few) 2 1 4 3
   2 (Many) 1 0 0.50 4 3 0.34 0.06
No. pts with improvement - % 4/5(80) 4/9(44) 0.30
Lobular Inflammation
Score – no. of subjects
   0 (0 or 1 focus) 2 4 0 1
   1 (2-4 foci per 200x field) 1 1 5 4
   2 (>4 foci per 200x field) 2 0 0.17 4 4 0.77 0.005
No. pts with improvement - % 5/5(100) 2/9(22) 0.02
NAS
Median (range) 5 (1-7) 2 (0-5) 0.05 5 (2-8) 5 (1-7) 0.29 0.02
Pts with a reduction in score of  ≥ 2* – no./total no. (%) 4/5(80) 2/9(22) 0.09
Fibrosis
Score – no. of subjects
   0 (None) 2 4 3 5
   1 (Perisinusoidal or periportal) 2 1 2 1
   2 (Perisinusoidal and portal or periportal) 1 0 2 0
   3 (Bridging fibrosis) 0 0 2 1
   4 (Cirrhosis) 0 0 0.50 0 2 1.0 0.13
No. pts with improvement - % 4/5(80) 6/9(67) 1.0
Pts with a reduction in score of  ≥ 2* – no./total no. (%) 4/5(80) 5/9(56) 0.58
NASH§
Pts with resolution of NASH –no./total no. (%) 2/3(67) 2/8(25) 0.49
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Figure 3: Effect of diet and exercise interventions on steatosis and disease severity.
Individual change in steatosis (Panel A, *p<0.05 Wilcoxon signed rank test) and median score change in NAFLD activity Score (NAS) (Panel B, *p<0.05Wilcoxon signed 
rank test), Lobular inflammation (Panel C, p<0.05RMANOVA for time x treatment difference between groups at 6 months) and Fibrosis (Panel D, p=NS) assessed by 
liver biopsy pre and post intervention. Symbols  depicts DIWL and  depicts EX group.
Figure 4: Factors associated with change in steatosis after intervention.
Change in steatosis was correlated with overall weight loss rs=0.82 p<0.0001 (Panel A) and change in fibrosis assessed by Brunt scorers=0.64. p=0.02 (Panel B). 
Symbols  depicts DIWL and  depicts EX group.
Figure 5: Effect of diet and exercise interventions on peripheral insulin sensitivity.
Individual response of peripheral (muscle) insulin sensitivity index to DIWL and EX, illustrated by total glucose disposal (TGD) rate/steady state plasma insulin levels, 
during the hyperinsulinemic-euglycaemic clamp. Pre- and post-comparison using paired Wilcoxon signed rank test was not significantly different after either intervention. 
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exercise training for six months showed cardiometabolic improvements 
including reduced visceral adiposity, increased aerobic fitness and 
improvements in HDL cholesterol. But in the absence of weight loss, 
histological improvement in liver disease was not achieved. In contrast, 
dietary induced weight reduction, achieved while still maintaining a 
very sedentary lifestyle, led to improvements in blood pressure, HMW 
adiponectin and histological features of NASH. Both interventions 
achieved an equivalent improvement in fasting hepatic insulin 
sensitivity but showed a variable or absent peripheral (muscle) response 
in insulin sensitivity. 
The histological results of this study are unique and were chosen 
as the primary outcome variable due to the lack of data regarding 
exercise prescription that may prevent or delay progression of NASH 
[7]. The lack of improvement in steatosis after circuit training contrasts 
earlier studies of exercise in NAFLD, which have typically used shorter 
exercise prescriptions and different techniques to assess steatosis. These 
previous studies have shown a 10-20% relative reduction in hepatic 
fat measured by MRS [26-28]. This is a real, yet small effect compared 
to the ~70% relative reduction in MRS assessed hepatic fat seen after 
10% body weight loss [29]. While MRS and histological assessment 
of steatosis are correlated [30], they are not equivalent or comparable 
units of measure. MRS measures absolute hepatic triglyceride content 
whereas histological assessment reflects the proportion of hepatocytes 
with visible triglyceride droplets and modest changes in total 
triglyceride content assessed by MRS may not be reflected in histological 
quantitation of steatosis. The additional value of histological assessment 
is the ability to assess features of NASH including inflammation, 
hepatocyte ballooning and fibrosis, all of which cannot be distinguished 
by MRS and have not been reported in any previous study.
In the current study, improvements in steatosis correlated with 
overall weight loss, rather than specific fat loss, perhaps reflecting the 
need for a calorie deficit in order to mobilize steatosis. The greater 
improvement in hepatic inflammation after DIWL compared to EX may 
in part be due to the reduction/mobilisation of steatosis and a healthier 
adipokine profile as suggested by the relationship between improved 
lobular inflammation and HMW adiponectin. Patients in the DIWL 
group were weight stable for at least two weeks prior to re-biopsy. Some 
patients remained considerably overweight (despite significant weight 
loss) and the long-term histological consequences of ceasing calorie 
restriction while maintaining a lower, yet still overweight body mass 
index is unknown. The only variable associated with improvement in 
fibrosis was a decrease in steatosis and this was independent of weight 
and fat loss. This suggests that a reduction in steatosis (in this study 
achieved via calorie restriction) is necessary for an improvement in 
liver disease severity, irrespective of improvements in other metabolic 
risk factors.
Improvement in muscle insulin sensitivity was modest at best, with 
a smaller change in TGD compared to other studies of weight loss in 
obese patients without NASH [31]. This small to no effect of exercise 
alone on markers of insulin resistance in NAFLD has been reported by 
others [27,28] and suggests the type and intensity of exercise prescription 
(in the absence of weight loss)still requires further investigation to 
determine what prescription will best target the profound muscle 
insulin resistance associated with NASH. A similar phenomenon was 
seen when aerobic exercise without weight loss did not change lipid 
kinetics (VLDL secretion) in NAFLD [26]. The plausible role of genetic, 
inflammatory or disease specific influences on insulin resistance 
in NASH [32] may need to be considered when prescribing lifestyle 
advice (dose and intensity of exercise and/or amount of weight loss) 
to this patient population. The weight loss experienced after DIWL 
involved losses from both fat and lean mass. Given that muscle insulin 
resistance is likely the primary driver of progression to type 2 diabetes 
in this patient population [33], the independent and combined effects 
of DIWL and different types of EX on body composition and muscle 
metabolism is clinically relevant and warrants further exploration.
While there is a paucity of well-controlled studies investigating the 
benefits of exercise alone on hepatic insulin resistance, it seems that 
any effect may be independent of obesity, change in weight, energy 
balance, or presence of steatosis. The amelioration of steatosis in the 
DIWL did not produce a significantly greater improvement in hepatic-
IR to that seen with EX where severe steatosis remained. Equivalent 
improvements in hepatic insulin sensitivity have been demonstrated 
in both lean and obese study participants after 12 weeks of a high 
intensity exercise program [31]. Our study supports the observation 
that improvements in hepatic-IR can be distinct from muscle and can 
be demonstrated after both diet-induced weight loss and EX training 
without weight loss. This suggests DIWL and EX may have either a 
shared mechanism (such as an increase in whole body fat oxidation) 
or equally effective separate mechanism for improving hepatic-IR, 
independent of steatosis. 
Visceral fat increases metabolic and cardiovascular risk but the 
most effective method for targeting reductions in visceral adiposity 
while maintaining muscle mass is unclear. Evidence exists to support 
both aerobic training alone [34] and resistance training [35] as a means 
to reduce visceral fat, but most studies are in conjunction with some 
weight reduction. In this study, both DIWL and EX reduced visceral 
adiposity. The potential role of adipose tissue in the progression of 
liver disease has been highlighted [36,37] and our data supports the 
existence of cross-talk between fat and liver, firstly by demonstrating 
correlations at baseline between Adipo-IR and both hepatic-IR and 
fibrosis; and secondly by demonstrating that improvements in Adipo-
IR and whole body fat oxidation are linked to beneficial changes in 
hepatic-IR. Adiponectin is an insulin sensitising adipokine, with the 
HMW isomer having a particular effect on the liver [38]. Adiponectin 
has been proposed as a key contributor to the histological benefits 
of thiazolidinedione therapy of NASH [39]. The increase in HMW 
adiponectin after DIWL and its association with improved lobular 
inflammation supports a liver specific benefit associated with the 
HMW adiponectin isomer. Improving the metabolic “fitness” of fat 
tissue appears to be an important target for obese populations.
When proposing a therapeutic option for a chronic condition 
it is important to consider its acceptability for the target population. 
The circuit EX training was offered in a supervised environment and 
prescribed at a moderate intensity deemed safe for obese patients. 
Attendance was high and no adverse events were reported. However, 
sustaining behaviour change in unsupervised environments has not 
yet been established. All participants in the study maintained a very 
sedentary lifestyle outside of the study with no measurable aerobic 
activity above the intensity of slow walking. If similar weight losses 
to DIWL were to be achieved through exercise alone, a minimum of 
brisk walking for >1.5 hours every day would be required. A cross-
sectional study by Kistler et al. [40] supports the hypothesis that low to 
moderate physical activity may not be protective for the development 
of NASH, whereas vigorous activity greater than 150 minutes per week 
is associated with lower risk for severe fibrosis. As that amount of 
vigorous physical activity is well above that recommended for general 
health, this raises important clinical questions about what may be the 
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most appropriate intensity of exercise prescription for the prevention 
of NAFLD and the treatment of established NASH given the patient 
is likely to be overweight with little previous experience with intense 
physical activity. Further investigations of various combinations of 
diet, exercise and combined/simultaneous weight loss and exercise 
prescriptions are needed in this patient population.
Limitations
Requirement for liver biopsy made recruitment difficult and 
performing biopsies in a NAFLD control group with no intervention 
is ethically challenging, therefore the DIWL acted as a ‘standard care’ 
control group. However, even with natural fluctuation in histological 
features over time presumed, clear differences between the groups 
were still observed. The pilot study was small and powered for within 
group change in steatosis and glucose disposal rate only, therefore 
a type 2 error is possible for the remaining outcomes. The variability 
in peripheral metabolic response to intervention was not anticipated 
and larger numbers are recommended to confirm our observations. 
The study excluded patients with type 2 diabetes and so may not be 
representative of the proportion of patients with NAFLD and comorbid 
diabetes, which may be common in a clinical setting. The six-month 
time frame may not have been sufficient to detect changes in some 
clinical variables. 
Conclusions
These results demonstrate that dietary induced weight loss and 
exercise alone have distinct and complementary benefits for NAFLD. 
Circuit exercise is safe, well accepted and efficacious for improving 
cardiometabolic risk in patients with NAFLD. However this dose 
of exercise, without concomitant weight loss, was inadequate for 
histological improvements in liver disease severity or substantial 
benefit to peripheral insulin sensitivity after 6 months of therapy. 
The pilot study outcomes should stimulate further development of 
different exercise protocols (type, frequency and intensity) to address 
these disease-specific conditions and add new insight to the practice 
guidelines for the management of NAFLD.
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